AstraZeneca Pharma India Limited has received shareholder approval to shift its registered office from the State of Karnataka to the State of Maharashtra. This strategic move, finalized through a special resolution passed via postal ballot, necessitates an amendment to the company’s Memorandum of Association. The transition is now subject to final regulatory clearances under the Companies Act, 2013, before the relocation can be officially enacted.
Shareholder Approval for Corporate Relocation
AstraZeneca Pharma India Limited has officially confirmed that its shareholders have greenlit the proposal to relocate the company’s registered office. The decision to move from Karnataka to Maharashtra was ratified through a special resolution. The results of the remote e-voting process, which concluded on May 12, 2026, indicate strong support for this structural change.
Next Steps and Regulatory Requirements
Following the successful vote, the company will now initiate the necessary procedures to amend the 2nd Clause of its Memorandum of Association. While the shareholder mandate is a critical milestone, the relocation remains contingent upon receiving the final requisite approvals from the relevant authorities as stipulated by the Companies Act, 2013, and its associated governing rules.
Source: BSE
